chronic hepatitis and liver fibrosis
Conditions
Interventions
Experimental Group:Ganshuang Keli+Silybin Meglumine
Control Group:Silybin Meglumine
Sponsors
302 Hospital of PLA
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. aged 18 to 65 years, both gender; 2. The HBV marker positive reaction continues at least 6 months before recruitment; 3. The serum ALT level is 1.5 to 10 times higher than normal upper threshold; or at least two items of the four items of fibrosis is 1.2 times higher than normal upper threshold; or liver tissue pathology finding suggested the inflammation G=2 or fibrosis S=2; 4. Serum total bilirubin less than 51 umol/L; 5. Not received anti-fibrosis and immunomodulatory agents therapy in past six months of before recruitment; 6. The patient or the legal representative can understand and sign the informed consent, to be able to communicate with the researchers and cooperate with the researchers to perform the protocol.
Exclusion criteria
Exclusion criteria: 1. To be confirmed with decompensated cirrhosis; original/metastatic liver cancer; Autoimmune liver disease; Drug-induced liver disease; Alcoholic liver disease; Toxic liver damage; 2. PLT200 ng/ml; 5. Has a history of alcoholism or drug addiction; History of peptic ulcer or asthma; Serious endocrine and heart, lung, and kidney diseases; 6. Using other drugs or therapies which will affect the assessment or the treatment of the hepatitis during the study; 7. The patient is treating or in past three months treated by the same drugs; 8. Pregnancy woman, lactating woman or the woman plan to pregnancy; 9. Mental disease patient.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| liver function indicators;serum fibrosis index;Immunological indicators;Clinical indications;The degree of fibrosis;Fibroscan Liver stiffness;Portal vein and splenic vein width?spleen pachydia; | — |
Countries
China
Contacts
Public ContactChen Yu
302 Hospital of PLA
Outcome results
None listed